Basics of Chimeric Antigen Receptor CAR Immunotherapy

Produk Detail:
  • Author : Mumtaz Y. Balkhi
  • Publisher : Academic Press
  • Pages : 92 pages
  • ISBN : 0128197471
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Basics of Chimeric Antigen Receptor CAR Immunotherapy

Download or Read online Basics of Chimeric Antigen Receptor CAR Immunotherapy full in PDF, ePub and kindle. this book written by Mumtaz Y. Balkhi and published by Academic Press which was released on 31 July 2019 with total page 92 pages. We cannot guarantee that Basics of Chimeric Antigen Receptor CAR Immunotherapy book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols Provides unique authority as the editor has worked directly with CARs Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

Basics of Chimeric Antigen Receptor CAR Immunotherapy

Basics of Chimeric Antigen Receptor  CAR  Immunotherapy
  • Author : Mumtaz Y. Balkhi
  • Publisher : Academic Press
  • Release : 31 July 2019
GET THIS BOOK Basics of Chimeric Antigen Receptor CAR Immunotherapy

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application

Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality

Part I  Understanding Cancer Immunotherapy  A brief Review  Part II      What is Chimeric Antigen Receptor  CAR T Cell Therapy  An Emerging Cancer Treatment Modality
  • Author : Dr. Hakim Saboowala
  • Publisher : Dr.Hakim Saboowala
  • Release : 04 May 2020
GET THIS BOOK Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality

Part I- Understanding Cancer Immunotherapy: A brief Review. Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work by: Stopping or slowing the growth of cancer cells Stopping cancer from spreading to other parts of the body Helping the immune system work better at destroying cancer cells There are

Fast Facts CAR T Cell Therapy

Fast Facts  CAR T Cell Therapy
  • Author : R.J. Buka,A.J. Kansagra
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 26 January 2021
GET THIS BOOK Fast Facts CAR T Cell Therapy

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book
  • Author : Daniel W. Lee,Nirali N. Shah
  • Publisher : Elsevier Health Sciences
  • Release : 30 November 2019
GET THIS BOOK Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging

Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas and Exploration of Neuron opc Synaptic Connectivity in the Context of Adaptive Myelination

Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas and Exploration of Neuron opc Synaptic Connectivity in the Context of Adaptive Myelination
  • Author : Christopher Mount
  • Publisher : Unknown
  • Release : 25 September 2021
GET THIS BOOK Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas and Exploration of Neuron opc Synaptic Connectivity in the Context of Adaptive Myelination

Histone 3 K27M mutated diffuse midline glioma (H3K27M DMG) is a universally fatal pediatric brain tumor. Despite improved understanding of the molecular origins of this disease, translations to improvement in clinical outcomes have yet to materialize. To date, there has been little target exploration for immunotherapy applications in H3K27M DMG. In this thesis, I describe my work that elucidated substantial preclinical efficacy of chimeric antigen receptor (CAR)-bearing T cells targeting the disialoganglioside GD2 as an

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels

CAR T Cell Therapies for Non Hematopoietic Malignancies  Taking Off The Training Wheels
  • Author : Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus
  • Publisher : Frontiers Media SA
  • Release : 24 April 2020
GET THIS BOOK CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels

Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition

Immunotherapy Using Chimeric Antigen Receptor Macrophage

Immunotherapy Using Chimeric Antigen Receptor Macrophage
  • Author : Peng Fei Huang
  • Publisher : Unknown
  • Release : 25 September 2021
GET THIS BOOK Immunotherapy Using Chimeric Antigen Receptor Macrophage

Chimeric antigen receptor (CAR) T cell immunotherapy has become one of the most prominent and leading cancer therapies due to its remarkable success in targeting hematological malignancies. Unfortunately, CAR-T cell immunotherapy has not had the same amount of success in solid tumors due to the challenging tumor's immunosuppressive microenvironment. Therefore, we hypothesize the use of macrophages as a vessel for CAR immunotherapy due to their associate with tumors as TAMs and also the tumors ability to secrete various chemokines that

Defining Optimal T Cell Characteristics for Pediatric Chimeric Antigen Receptor CAR T Cell Trials

Defining Optimal T Cell Characteristics for Pediatric Chimeric Antigen Receptor  CAR  T Cell Trials
  • Author : Julie M. Rivers
  • Publisher : Unknown
  • Release : 25 September 2021
GET THIS BOOK Defining Optimal T Cell Characteristics for Pediatric Chimeric Antigen Receptor CAR T Cell Trials

Background: Engineered chimeric antigen receptor (CAR) T cells have emerged as a powerful, highly personalized immunotherapy in pediatric cancer. Early phase clinical trials using CAR T cells targeting CD19 have resulted in complete response (CR) rates as high as 93% in children with relapsed and refractory acute lymphoblastic leukemia (ALL). Despite this success, there are many challenges that must be overcome before CAR T cell therapy can be used routinely in pediatric ALL or other malignancies. Objective: To develop novel biomarkers

Fast Facts CAR T Cell Therapy

Fast Facts  CAR T Cell Therapy
  • Author : Richard J. Buka,Ankit J. Kansagra
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 28 February 2021
GET THIS BOOK Fast Facts CAR T Cell Therapy

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare

Cancer Immunotherapy

Cancer Immunotherapy
  • Author : David B. Teplow
  • Publisher : Academic Press
  • Release : 03 August 2019
GET THIS BOOK Cancer Immunotherapy

Cancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to different approaches to cancer immunotherapy, with this release focusing on TNFR2 in cancer immunology and immunotherapy, From the Hellstrom paradox towards cancer cure, CAR T-cell treatment of T-cell malignancy , Immunotherapy of pancreatic cancer, Cancer stem cell immunology/immunotherapy, Cytokine release syndrome, Tumor cell-based mechanisms of resistance to immune attack, and Mushroom compounds in cancer immunotherapy. Includes

The Basics of Cancer Immunotherapy

The Basics of Cancer Immunotherapy
  • Author : Haidong Dong,Svetomir N. Markovic
  • Publisher : Springer
  • Release : 05 January 2018
GET THIS BOOK The Basics of Cancer Immunotherapy

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize

Applications of Nanomaterials in Human Health

Applications of Nanomaterials in Human Health
  • Author : Firdos Alam Khan
  • Publisher : Springer Nature
  • Release : 20 June 2020
GET THIS BOOK Applications of Nanomaterials in Human Health

This book reviews the various applications of nanotechnology in human health. The introductory chapters focus on the classifications, types, synthesis, and characterization of various types of nanomaterials, while subsequent chapters highlight current applications of nanomaterials in the diagnosis and treatment of microbial and viral infections, and also in stem cell biology and regenerative medicine. Further, the book explores the potential role of nanomaterials in connection with neuronal differentiation, neuronal protection, and neurological diseases. It demonstrates the use of nanotechnology to

Problem Solving in Cancer Immunotherapy

Problem Solving in Cancer Immunotherapy
  • Author : Ruth E Board,Paul Nathan,Tom Newsom-Davis,Sophie Papa,Peter Johnson
  • Publisher : Evidence-based Networks Ltd
  • Release : 07 January 2019
GET THIS BOOK Problem Solving in Cancer Immunotherapy

· a multidisciplinary review including the latest developments in cancer immunotherapy from over 70 experts and leaders · hands-on, practical guide to immunotherapy for hospital and community teams, GPs and allied care professionals, including 23 case studies · a valuable learning tool for doctors, nurses, graduate medical trainees, care managers and anyone involved in cancer care produced in partnership with the Association of Cancer Physicians (ACP) Editors and authors have drawn on their expertise and growing experience of immunotherapy to produce this practical guide to